Management of vaccinations in patients with non-Hodgkin lymphoma

Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non-Hodgkin lymphomas (NHLs). The COVID-19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life-threatening SARS...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2024-05, Vol.204 (5), p.1617-1634
Main Authors: Merli, Michele, Costantini, Andrea, Tafuri, Silvio, Bavaro, Davide Fiore, Minoia, Carla, Meli, Erika, Luminari, Stefano, Gini, Guido
Format: Article
Language:English
Subjects:
CD20 antigen
COVID-19
Immune response
Immunocompromised hosts
Infectious diseases
Monoclonal antibodies
Non-Hodgkin's lymphoma
Severe acute respiratory syndrome coronavirus 2
Vaccines
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vaccinations are fundamental tools in preventing infectious diseases, especially in immunocompromised patients like those affected by non-Hodgkin lymphomas (NHLs). The COVID-19 pandemic made clinicians increasingly aware of the importance of vaccinations in preventing potential life-threatening SARS-CoV-2-related complications in NHL patients. However, several studies have confirmed a significant reduction in vaccine-induced immune responses after anti-CD20 monoclonal antibody treatment, thus underscoring the need for refined immunization strategies in NHL patients. In this review, we summarize the existing data about COVID-19 and other vaccine's efficacy in patients with NHL and propose multidisciplinary team-based recommendations for the management of vaccines in this specific group of patients.
ISSN:0007-1048
1365-2141
1365-2141
DOI:10.1111/bjh.19422